Ultime notizie per Geovax Labs (NASDAQ:GOVX) Azioni

Geovax Labs

Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors.

Geovax Labs Inc

<a href="https://worldhealthorg.shinyapps.io/mpx_global/" title="https://worldhealthorg.shinyapps.io/mpx_global/">https://worldhealthorg.shinyapps.io/mpx_global/</a>

Biotech

News

General

AEMD

APDN

CMRX

GOVX

TNXP

VRAX

World Health Organization Says Mpox Continues To Constitute A Public Health Emergency Of International Concern

HC Wainwright &amp; Co. analyst Vernon Bernardino reiterates Geovax Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOVX#NASDAQ">GOVX</a>) with a Buy and maintains $8 price target.

Price Target

Reiteration

Analyst Ratings

HC Wainwright & Co. Reiterates Buy on Geovax Labs, Maintains $8 Price Target

D. Boral Capital analyst Jason Kolbert maintains Geovax Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOVX#NASDAQ">GOVX</a>) with a Buy and maintains $18 price target.

D. Boral Capital Maintains Buy on Geovax Labs, Maintains $18 Price Target

GOVXW

GeoVax Reports Interim Data For Phase 2 Trial Of COVID-19 Booster Vaccine GEO-CM04S1 In CLL Patients; DSMB Recommends Continued Enrollment As GEO-CM04S1 Outperforms mRNA Vaccine In Immune Response Evaluation

GeoVax Labs Received Notice From Nasdaq Notifying The Company That, Co. Complies With Stockholders' Equity Listing Rule

<h3>Gainers</h3>
<ul>
<li>Mersana Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRSN#NASDAQ">MRSN</a>) shares rose 22.7% to $2.7 during Wednesday's pre-market session. The market value of their outstanding shares is at $331.2 million. As per the news, the Q3 earnings report came out today. </li>
<li>Kairos Pharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/KAPA#AMEX">KAPA</a>) stock rose 19.74% to $2.46. The market value of their outstanding shares is at $31.5 million. </li>
<li>Calidi Biotherapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CLDI#AMEX">CLDI</a>) shares increased by 18.48% to $2.5. The market value of their outstanding shares is at $29.1 million. The company's, Q3 earnings came out yesterday. </li>
<li>Natera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>) shares rose 16.66% to $157.64. The company's market cap stands at $19.4 billion. As per the news, the Q3 earnings report came out yesterday. </li>
<li>Ensysce Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSC#NASDAQ">ENSC</a>) stock increased by 15.62% to $0.78. The market value of their outstanding shares is at $11.6 million. The company's, Q3 earnings came out yesterday. </li>
<li>Lexeo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LXEO#NASDAQ">LXEO</a>) stock increased by 12.61% to $8.66. The company's market cap stands at $286.3 million. The company's, Q3 earnings came out today. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Syros Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYRS#NASDAQ">SYRS</a>) shares decreased by 85.6% to $0.39 during Wednesday's pre-market session. The market value of their outstanding shares is at $10.5 million. </li>
<li>GlucoTrack (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCTK#NASDAQ">GCTK</a>) stock decreased by 72.24% to $0.44. The market value of their outstanding shares is at $2.5 million. </li>
<li>Psyence Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) stock fell 23.4% to $0.05. The company's market cap stands at $2.9 million. </li>
<li>CERo Therapeutics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERO#NASDAQ">CERO</a>) shares declined by 20.03% to $0.21. The market value of their outstanding shares is at $32.1 million. </li>
<li>Geovax Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOVX#NASDAQ">GOVX</a>) shares declined by 20.0% to $2.6. The company's market cap stands at $22.1 million. As per the press release, Q3 earnings came out yesterday. </li>
<li>Virpax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRPX#NASDAQ">VRPX</a>) shares fell 17.6% to $0.51. The market value of their outstanding shares is at $2.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

CERO

CLDI

ENSC

GCTK

KAPA

LXEO

MRSN

NTRA

SYRS

VRPX

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

WIIM

GeoVax Labs shares are trading lower. The company reported Q3 financial results.

Geovax Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOVX#NASDAQ">GOVX</a>) reported quarterly losses of $(0.91) per share which beat the analyst consensus estimate of $(1.48) by 38.51 percent. The company reported quarterly sales of $2.789 million which beat the analyst consensus estimate of $918.750 thousand by 203.56 percent.

Earnings

Earnings Beats

Geovax Labs Q3 2024 GAAP EPS $(0.91) Beats $(1.48) Estimate, Sales $2.789M Beat $918.750K Estimate

ABOS

ABSI

ACNT

ACTG

AENT

AGEN

AIOT

AIRG

ALIT

ALTG

AMBC

AMPS

AMTX

APEI

AREB

ARIS

ARMN

ATRA

AUTL

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

AXSM

AZTA

BHIL

BLDE

BLFS

BLTE

The Beachbody Company, Inc. Class A Common Stock

BODI

BRTX

BTMD

BTTR

BWAY

BXSL

BZFD

CAMT

CART

CATX

CAVA

CBAT

CBLL

CCLD

CGEN

CHGG

CHMI

CLSD

CNNE

CRNX

CRON

CRVS

CRWS

CVAC

CXAI

DAVA

DAVE

DRCT

DYAI

EARN

EGAN

ELMD

ETON

EVCM

EVGO

EYEN

FENG

FGEN

FIHL

FLNG

FOUR

FTCI

GENI

GENK

GMGI

GRAL

GRDN

GROV

GRPN

GRVY

Earnings Scheduled For November 12, 2024

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58ad9359b85e930001f9718e/jason-wittes">Roth MKM analyst Jason Wittes </a>initiated coverage on TriSalus Life Sciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLSI#NASDAQ">TLSI</a>) with a Buy rating and announced a price target of $11. TriSalus Life Sciences shares closed at $4.23 on Friday. <a href="https://www.benzinga.com/quote/TLSI/analyst-ratings">See how other analysts view this stock</a>.</li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/606af1536538960001bced45/james-molloy">Alliance Global Partners analyst James Molloy</a> initiated coverage on GeoVax Labs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOVX#NASDAQ">GOVX</a>) with a Buy rating and announced a price target of $15. Geovax Labs shares closed at $1.95 on Friday. <a href="https://www.benzinga.com/quote/GOVX/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying GOVX stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="574" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/11081824/image-110-1024x574.png" alt="" class="wp-image-640412" style="width:566px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/11081824/image-110-1024x574.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/11081824/image-110-300x168.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/11081824/image-110-768x431.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/11081824/image-110.png 1198w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/11/41871463/dow-sp-500-notch-best-week-of-year-as-tesla-surges-post-trump-win-investor-sentiment-improves-fear-greed-index-remains-in-neutral-zone">Dow, S&amp;P 500 Notch Best Week Of Year As Tesla Surges Post Trump Win: Investor Sentiment Improves, Fear &amp; Greed Index Remains In &#8216;Neutral&#8217; Zone</a></li>
</ul>

Pre-Market Outlook

Markets

Trading Ideas

MRCY

TLSI

UEIC

This GeoVax Labs Analyst Begins Coverage On A Bullish Note; Here Are Top Initiations For Monday

Geovax Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOVX#NASDAQ">GOVX</a>) is preparing to release its quarterly earnings on Tuesday, 2024-11-12. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Geovax Labs to report an earnings per share (EPS) of $-1.48.
The market awaits Geovax Labs's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Earnings History Snapshot</h3>
During the last quarter, the company reported an EPS beat by $2.44, leading to a 1.11% drop in the share price on the subsequent day.
Here's a look at Geovax Labs's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-4.43</td>
<td>-3.15</td>
<td>-2.78</td>
<td>-3.6</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-1.99</td>
<td>-2.47</td>
<td>-3.94</td>
<td>-4.8</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-1.0%</td>
<td>1.0%</td>
<td>-1.0%</td>
<td>-2.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1731344529_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Geovax Labs were trading at $1.95 as of November 08. Over the last 52-week period, shares are down 72.81%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<a href="https://www.benzinga.com/quote/GOVX/earnings">To track all earnings releases for Geovax Labs visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Preview: Geovax Labs

Alliance Global Partners analyst James Molloy initiates coverage on Geovax Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOVX#NASDAQ">GOVX</a>) with a Buy rating and announces Price Target of $15.

Initiation

Alliance Global Partners Initiates Coverage On Geovax Labs with Buy Rating, Announces Price Target of $15

<a href="https://www.business-standard.com/health/new-study-claims-mpox-clade-la-has-evolved-to-spread-from-human-to-human-nc-124111100528_1.html" title="https://www.business-standard.com/health/new-study-claims-mpox-clade-la-has-evolved-to-spread-from-human-to-human-nc-124111100528_1.html">https://www.business-standard.com/health/new-study-claims-mpox-clade-la-has-evolved-to-spread-from-human-to-human-nc-124111100528_1.html</a>

MRNA

India's Business Standard Reported New Study Claims Mpox Clade la Has Evolved To Spread From Human To Human, Citing October 24 Uploaded Paper On Virologica

https://www.reuters.com/world/uk/uk-detects-two-more-cases-new-mpox-variant-2024-11-04/#:~:text=LONDON%2C%20Nov%204%20(Reuters),to%20the%20population%20remained%20low.

Macro Notification

'UK detects two more cases of new mpox variant' - Reuters

BWVI

WHO Expands Emergency Use List For Mpox Diagnostics, Adds Cepheid's Xpert Mpox PCR Test And Roche's Cobas MPXV Assay As PCR-Based Gold Standard Options

<a href="https://economictimes.indiatimes.com/news/international/world-news/new-mpox-variant-detected-in-germany-health-authority/articleshow/114463317.cms">https://economictimes.indiatimes.com/news/international/world-news/new-mpox-variant-detected-in-germany-health-authority/articleshow/114463317.cms</a>
An infection with the new mpox variant clade 1b has been detected in Germany for the first time, the Robert Koch Institute health authority said on Tuesday. &nbsp;

Reported Earlier, 'New Mpox Variant Detected In Germany: Health Authority' - The Economic Times

SNGX

HHS Says CDC To Issue Level 3 Travel Health Notice For Rwanda On Oct 7; Rwanda Has Reported 49 Cases And 12 Deaths From Marburg Virus As Of Oct 6; CDC To Begin Public Health Entry Screening For Travelers Entering US From Rwanda Starting Week Of Oct 14; Level 3 Notice Recommends Reconsideration Of Nonessential Travel To Rwanda

Alliance Global Partners analyst James Molloy initiated coverage of GeoVax Labs (GOVX) with a Buy rating and $15 price target Lead candidate GEO-CM...

GeoVax Labs initiated with a Buy at Alliance Global Partners

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need...

Pinterest, Cisco upgraded: Wall Street's top analyst calls

GeoVax GAAP EPS of -$0.91 beats by $0.57, revenue of $2.79M beats by $1.87M

GeoVax Labs, Inc. (GOVX) Q3 2024 Earnings Call Transcript

Noble Financial analyst Robert LeBoyer reiterated a Buy rating on GeoVax Labs (GOVX – Research Report) today and set a price target of $10.00. The ...

Noble Financial Keeps Their Buy Rating on GeoVax Labs (GOVX)

Vernon Bernardino, an analyst from H.C. Wainwright, reiterated the Buy rating on GeoVax Labs (GOVX – Research Report). The associated price target ...

GeoVax Labs: Promising Developments in COVID-19 Vaccine and Therapeutics Propel Buy Rating

First mpox case linked to African outbreak reported in U.S.

GeoVax Labs (GOVX) announced the completion of an interim data review by the Data Safety Monitoring Board (DSMB) for the ongoing Phase 2 clinical t...

GeoVax Labs announces interim data from Phase 2 trial of Vaccine technology

Noble Financial analyst Robert LeBoyer reiterated a Buy rating on GeoVax Labs (GOVX – Research Report) today and set a price target of $12.00. The ...

GeoVax Labs (GOVX) Receives a Buy from Noble Financial

The World Health Organizatiton said that Director-General Dr. Tedros Adhanom Ghebreyesus, agreeing with the advice of the IHR Emergency Committee, ...

WHO determines mpox upsurge still constitutes public health emergency

BLMN

BVNKF

BVNRY

CODX

CSCO

FTNT

LCID

NRDY

PINS

RHHBF

RHHBY

SIGA

SMAR

STLA

Press Releases

Presenting on the Emerging Growth Conference 74 Day 2 on August 22 Register Now

Health Care

Registration is Now Open for Tribe Public's Webinar Event "Now Is Not the Time to Monkey(pox) Around" Featuring GeoVax Lab's CEO

GeoVax to Raise Approximately $5.0 Million of Gross Proceeds in Offering Priced At-the-Market

GeoVax to Participate in Upcoming Investor Conferences in September

Presenting on the Emerging Growth Conference 75 Day 1 on September 25 Register Now

Presenting on the Emerging Growth Conference 75 Day 2 on September 26

GeoVax to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

GeoVax to Report Third Quarter 2024 Financial Results and Provide Corporate Update on November 12, 2024

GeoVax Reports Third Quarter 2024 Financial Results and Provides Business Update

GeoVax Announces Positive Interim Data Review for Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia

Comments

Geovax Labs

Notizie

Ultime notizie per Geovax Labs (NASDAQ:GOVX) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO